Tocilizumab actemra
Tocilizumab Actemra is a biologic medication developed by Roche. It is designed to inhibit the interleukin-6 (IL-6) receptor, which plays a role in inflammatory processes. The core function of Tocilizumab Actemra is to modulate the immune system response.
Lab products found in correlation
3 protocols using tocilizumab actemra
Tocilizumab for Steroid-Refractory Pre-Engraftment Syndrome
Multiparameter Analysis of Immune Checkpoint Markers
Breast Cancer Cell Line Characterization
Cells were treated with the following chemicals and antibodies diluted in serum-free medium: FPR antagonist Cyclosporin H (CsH-Sigma, used at 1 µM), neutralizing anti-IL-6 antibody (Tocilizumab Actemra, Roche, used at 2 µg/mL), STATTIC (STC-Sigma 1 and 5 µM) and recombinant IL-6 (rIL-6, Thermo Fisher Scientific, used at 1 µg/mL).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!